SI2893936T1 - Glutaril histamin za zdravljenje in profilakso bolezni, ki jih povzročajo virusi, ki vsebujejo (+)RNA - Google Patents
Glutaril histamin za zdravljenje in profilakso bolezni, ki jih povzročajo virusi, ki vsebujejo (+)RNA Download PDFInfo
- Publication number
- SI2893936T1 SI2893936T1 SI201331011T SI201331011T SI2893936T1 SI 2893936 T1 SI2893936 T1 SI 2893936T1 SI 201331011 T SI201331011 T SI 201331011T SI 201331011 T SI201331011 T SI 201331011T SI 2893936 T1 SI2893936 T1 SI 2893936T1
- Authority
- SI
- Slovenia
- Prior art keywords
- pharmaceutically acceptable
- virus
- acceptable salt
- glutaryl
- histamine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (14)
- Glutaril histamin za zdravljenje in profilakso bolezni, ki jih povzročajo virusi, ki vsebujejo (+)RNA Patentni zahtevki1. Glutaril histamin ali njegova farmacevtsko sprejemljiva sol, za uporabo v preventivi ali zdravljenju bolezni, kijih povzročajo virusi, ki vsebujejo (+)RNA, ki pripadajo rodu Enterovirus ali rodu Flavivirus.
- 2. Glutaril histamin ali njegova farmacevtsko sprejemljiva sol, za uporabo po zahtevku 1, kjer je virus, ki pripada rodu Enterovirus izbran iz skupine, ki vsebuje rinoviruse, viruse Coxsackie in enteroviruse tip 71.
- 3. Glutaril histamin ali njegova farmacevtsko sprejemljiva sol, za uporabo po zahtevku 1, kjer so bolezni poslabšanja astme, kronična obstruktivna pljučna bolezen, bronhitis in mukoviscidoza, ki jih povzroča rinovirus.
- 4. Glutaril histamin ali njegova farmacevtsko sprejemljiva sol, za uporabo po zahtevku 1, kjer je virus, ki pripada rodu Flavivirus izbran iz skupine, ki vsebuje virus zahodnega Nila, virus denge, virus encefalitisa, ki ga prenašajo klopi, Saint-Louisov virus encefalitisa, Murray Valleyev virus encefalitisa in virus rumene mrzlice.
- 5. Glutaril histamin ali njegova farmacevtsko sprejemljiva sol, za uporabo po kateremkoli zahtevku od 1 do 4, kjer je glutaril histamin ali njegova farmacevtsko sprejemljiva sol administrirana v trdni dozirni obliki.
- 6. Glutaril histamin ali njegova farmacevtsko sprejemljiva sol, za uporabo po kateremkoli zahtevku od 1 do 5, kjer je odmerek glutaril histamina ali njegove farmacevtsko sprejemljive soli od 0,1 do 10 mg/kg telesne teže pacienta, ki mu administriramo glutaril histamin ali njegovo farmacevtsko sprejemljivo sol.
- 7. Glutaril histamin ali njegova farmacevtsko sprejemljiva sol, za uporabo po kateremkoli zahtevku od 1 do 6, kjer je en odmerek glutaril histamina 100 mg.
- 8. Glutaril histamin ali njegova farmacevtsko sprejemljiva sol, za uporabo po kateremkoli zahtevku od 1 do 7, kjer je čas trajanja administracije glutaril histamina od 5 dni do 12 mesecev.
- 9. Farmacevtski sestavek za uporabo v preventivi ali zdravljenju bolezni, ki jih povzročajo virusi, ki vsebujejo (+)RNA, ki pripadajo rodu Enterovirus ali rodu Flavivirus, kjer farmacevtski sestavek vsebuje učinkovito količino glutaril histamina ali njegove farmacevtsko sprejemljive soli.
- 10. Farmacevtski sestavek po zahtevku 9, za uporabo po zahtevku 9, kjer je učinkovita glutaril histamina ali njegove farmacevtsko sprejemljive soli od 0,1 do 10 mg/kg telesne teže pacienta, ki mu farmacevtski sestavek administriramo.
- 11. Farmacevtski sestavek po zahtevku 9, za uporabo po zahtevku 9 ali 10, kjer je odmerek glutaril histamina 100 mg, kadar je administriran enkrat dnevno.
- 12. Farmacevtski sestavek po zahtevku 9, za uporabo po kateremkoli zahtevku od 9 do 11, kjer je virus, ki pripada rodu Entero virus izbran iz skupine, ki vsebuje rinoviruse, viruse Coxsackie in enteroviruse tip 71.
- 13. Farmacevtski sestavek po zahtevku 9, za uporabo po kateremkoli zahtevku od 9 to 11, kjer je virus, ki pripada rodu Flavivirus izbran iz skupine, ki vsebuje virus zahodnega Nila, virus denge, virus encefalitisa, ki ga prenašajo klopi, Saint-Louisov virus encefalitisa, Murray Valleyev virus encefalitisa in virus rumene mrzlice.
- 14. Farmacevtski sestavek po zahtevku 9, za uporabo po kateremkoli zahtevku od 9 to 11, kjer so bolezni poslabšanja astme, kronična obstruktivna pljučna bolezen, bronhitis in mukoviscidoza, kijih povzroča rinovirus.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2012137097/15A RU2518314C2 (ru) | 2012-08-30 | 2012-08-30 | Способ и средство активации irf-3 для лечения и профилактики заболеваний, вызываемых (+) phk-содержащими вирусами |
| EP13833080.8A EP2893936B1 (en) | 2012-08-30 | 2013-08-29 | Glutaryl histamine for the treatment and prophylaxis of diseases caused by (+)rna-containing viruses |
| PCT/RU2013/000751 WO2014035297A1 (ru) | 2012-08-30 | 2013-08-29 | Способ и средство для лечения и профилактики заболеваний, вызываемых (+) рнк-содержащими вирусами |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2893936T1 true SI2893936T1 (sl) | 2018-07-31 |
Family
ID=50183972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201331011T SI2893936T1 (sl) | 2012-08-30 | 2013-08-29 | Glutaril histamin za zdravljenje in profilakso bolezni, ki jih povzročajo virusi, ki vsebujejo (+)RNA |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9820970B2 (sl) |
| EP (1) | EP2893936B1 (sl) |
| JP (1) | JP6328638B2 (sl) |
| CN (1) | CN104684569B (sl) |
| CA (1) | CA2883908C (sl) |
| CY (1) | CY1120158T1 (sl) |
| DK (1) | DK2893936T3 (sl) |
| EA (1) | EA028541B1 (sl) |
| ES (1) | ES2667342T3 (sl) |
| HK (1) | HK1210025A1 (sl) |
| HU (1) | HUE036805T2 (sl) |
| LT (1) | LT2893936T (sl) |
| PL (1) | PL2893936T3 (sl) |
| PT (1) | PT2893936T (sl) |
| RU (1) | RU2518314C2 (sl) |
| SI (1) | SI2893936T1 (sl) |
| WO (1) | WO2014035297A1 (sl) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9504673B2 (en) * | 2009-05-21 | 2016-11-29 | LTD “Valenta-Intellekt” | Agent for the prophylaxis and treatment of highly pathogenic infectious diseases |
| RU2628800C2 (ru) * | 2014-03-12 | 2017-08-22 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Амидные соединения, способы получения, применение в качестве средств для лечения и профилактики заболеваний, вызываемых рнк-содержащими вирусами |
| RU2746692C1 (ru) * | 2020-04-14 | 2021-04-19 | Общество С Ограниченной Ответственностью "Валента - Интеллект" | Новые составы 2-(имидазол-4-ил)-этанамида пентандиовой-1,5 кислоты для лечения и профилактики вирусных заболеваний |
| RU2770521C2 (ru) * | 2020-02-11 | 2022-04-18 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Жидкая лекарственная форма для лечения и профилактики гриппа и орви |
| RU2744854C1 (ru) * | 2020-02-11 | 2021-03-16 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Жидкая лекарственная форма для лечения и профилактики гриппа и орви |
| RU2770518C2 (ru) * | 2020-02-11 | 2022-04-18 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Жидкая лекарственная форма для лечения и профилактики гриппа и орви |
| CN114984030A (zh) * | 2022-06-23 | 2022-09-02 | 中国人民解放军海军军医大学 | 利巴韦林在制备抗蜱传脑炎病毒药物中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2141483C1 (ru) * | 1997-07-04 | 1999-11-20 | Небольсин Владимир Евгеньевич | Производные пептидов или их фармацевтически приемлемые соли, способ их получения, применение и фармацевтическая композиция |
| JP3838034B2 (ja) * | 1997-10-13 | 2006-10-25 | 大塚製薬株式会社 | Ｃ型肝炎治療効果の改善剤及びその応用 |
| KR20010043004A (ko) * | 1998-04-30 | 2001-05-25 | 개리 이. 프라이드만 | 피코르나 바이러스 억제 화합물, 그의 제조 방법 및 용도 |
| RU2191594C1 (ru) * | 2001-04-03 | 2002-10-27 | Григорян Седа Суреновна | Средство и способ повышения резистентности к инфекции |
| EP1369120B1 (en) * | 2002-06-03 | 2007-02-14 | National Health Research Institutes | Treatment of flavivirus infection |
| US7605138B2 (en) * | 2002-07-03 | 2009-10-20 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| RU2335495C2 (ru) * | 2005-06-15 | 2008-10-10 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | N-ацильные производные аминокислот, их фармацевтически приемлевые соли, фармацевтическая композиция и применение в качестве гиполипидемических средств |
| RU2338552C2 (ru) * | 2006-09-19 | 2008-11-20 | Владимир Евгеньевич Небольсин | Фармацевтическая композиция для ингаляции |
| US9504673B2 (en) * | 2009-05-21 | 2016-11-29 | LTD “Valenta-Intellekt” | Agent for the prophylaxis and treatment of highly pathogenic infectious diseases |
| RU2496512C1 (ru) * | 2012-03-14 | 2013-10-27 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Способ лечения вирусного гепатита с |
-
2012
- 2012-08-30 RU RU2012137097/15A patent/RU2518314C2/ru active
-
2013
- 2013-08-29 JP JP2015529749A patent/JP6328638B2/ja active Active
- 2013-08-29 CA CA2883908A patent/CA2883908C/en active Active
- 2013-08-29 PL PL13833080T patent/PL2893936T3/pl unknown
- 2013-08-29 ES ES13833080.8T patent/ES2667342T3/es active Active
- 2013-08-29 CN CN201380051087.9A patent/CN104684569B/zh active Active
- 2013-08-29 EA EA201590460A patent/EA028541B1/ru unknown
- 2013-08-29 WO PCT/RU2013/000751 patent/WO2014035297A1/ru active Application Filing
- 2013-08-29 EP EP13833080.8A patent/EP2893936B1/en active Active
- 2013-08-29 HU HUE13833080A patent/HUE036805T2/hu unknown
- 2013-08-29 US US14/424,860 patent/US9820970B2/en active Active
- 2013-08-29 DK DK13833080.8T patent/DK2893936T3/en active
- 2013-08-29 SI SI201331011T patent/SI2893936T1/sl unknown
- 2013-08-29 PT PT138330808T patent/PT2893936T/pt unknown
- 2013-08-29 LT LTEP13833080.8T patent/LT2893936T/lt unknown
-
2015
- 2015-11-02 HK HK15110781.5A patent/HK1210025A1/xx unknown
-
2018
- 2018-05-03 CY CY20181100465T patent/CY1120158T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2883908C (en) | 2019-06-04 |
| EP2893936A1 (en) | 2015-07-15 |
| CN104684569B (zh) | 2018-03-02 |
| PT2893936T (pt) | 2018-05-02 |
| DK2893936T3 (en) | 2018-05-28 |
| ES2667342T3 (es) | 2018-05-10 |
| JP6328638B2 (ja) | 2018-05-23 |
| LT2893936T (lt) | 2018-06-25 |
| EP2893936B1 (en) | 2018-04-04 |
| US20150209330A1 (en) | 2015-07-30 |
| RU2012137097A (ru) | 2014-03-10 |
| EA028541B1 (ru) | 2017-11-30 |
| HK1210025A1 (en) | 2016-04-15 |
| HUE036805T2 (hu) | 2018-07-30 |
| CY1120158T1 (el) | 2018-12-12 |
| WO2014035297A1 (ru) | 2014-03-06 |
| EA201590460A1 (ru) | 2015-06-30 |
| PL2893936T3 (pl) | 2018-09-28 |
| CN104684569A (zh) | 2015-06-03 |
| RU2518314C2 (ru) | 2014-06-10 |
| US9820970B2 (en) | 2017-11-21 |
| CA2883908A1 (en) | 2014-03-06 |
| EP2893936A4 (en) | 2016-03-16 |
| JP2015526513A (ja) | 2015-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2893936T1 (sl) | Glutaril histamin za zdravljenje in profilakso bolezni, ki jih povzročajo virusi, ki vsebujejo (+)RNA | |
| Chen et al. | Activity of andrographolide and its derivatives against influenza virus in vivo and in vitro | |
| KR20190071765A (ko) | 코로나 바이러스에 연관된 감염의 치료를 위한 항바이러스 조성물 | |
| CN102085311B (zh) | 预防或治疗感冒和/或流行性感冒的中药组合物及其制备方法和用途 | |
| BR112014000371A2 (pt) | derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença | |
| MY202109A (en) | Viral replication inhibitors | |
| MX2012007410A (es) | Compuestos antivirales novedosos. | |
| MD4430B1 (ro) | Compoziţii şi metode de tratament al hepatitei virale C | |
| EA201171376A1 (ru) | Производные тиено[2,3-b]пиридина в качестве ингибиторов репликации вируса | |
| WO2008024843A3 (en) | Combination therapy method for treating hepatitis c virus infection and pharmaceutical compositions for use therein | |
| WO2013098655A3 (en) | Vaccines directed against human enteroviruses | |
| NZ612105A (en) | Human milk oligosaccharides for modulating inflammation | |
| MY194294A (en) | Novel viral replication inhibitors | |
| JP2013520405A5 (sl) | ||
| WO2007003330A3 (de) | Pharmazeutische darreichungsformen enthaltend eine wirkstoffkombination von nifedipin und/oder nisoldipin und einem angiotensin-ii antagonisten | |
| Hudson | The use of herbal extracts in the control of influenza | |
| WO2010090494A3 (ko) | 5-벤질아미노살리실산 유도체 또는 이의 염의 의약 용도 | |
| WO2012142575A3 (en) | Monomeric trioxane amide sulfur compounds | |
| JP2011500589A5 (sl) | ||
| WO2013012835A3 (en) | Sirna useful in the treatment of flavivirus infection | |
| Ye et al. | Screening of eleven chemical constituents from Radix isatidis for antiviral activity | |
| CN102416067A (zh) | 预防和治疗流行性感冒的中药 | |
| WO2011055931A3 (ko) | 인플루엔자 바이러스 유래 질병의 예방 또는 치료용 조성물 | |
| Deryabin et al. | Effects of a nutrient mixture on infectious properties of the highly pathogenic strain of avian influenza virus A/H5N1 | |
| A Marathe et al. | Herbal cocktail as anti-infective: promising therapeutic for the treatment of viral diseases |